



J. B. Chemicals & Pharmaceuticals Limited

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.

Phone: 022-24822222/24930918 Fax : 022 – 2493 0534/ 2493 9633

CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, November 10, 2014:

Unaudited Financial Results for Q 2- 2014-15

J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its standalone unaudited financial results for the quarter ended on September 30, 2014. The company posted satisfactory performance during the quarter. The highlights of Y-o-Y results are as under:

(Rs. in crores)

Particulars	Q2-2014-15	Q2-2013-14
Net Sales	274.86	247.44
Other Operating income	5.40	5.75
Other Income	5.20	6.80
Total Revenue	285.46	259.99
Profit from ordinary activities after finance cost but before exchange fluctuation translation loss	50.51	46.44
Profit from ordinary activities before tax	42.68	40.27
Profit from ordinary activities after tax	31.89	33.14
EPS (Rs.) (FV 2)	3.76	3.91

The net sales for the quarter at Rs. 274.86 crores were 11% higher against net sales in the corresponding quarter in the previous year. However, this is strictly not comparable Y-o-Y due to commencement of sales and distribution in Russia & CIS countries by the wholly owned subsidiary company during Q1. The profit from operations before finance cost and depreciation at Rs. 62.77 crores was 12% higher against the same quarter in the previous year.

The domestic formulations business at overall sales of Rs. 106.27 crores registered growth of 17%. The prescription products sales at Rs. 97.39 crores registered growth of 19%, while contrast media products sales at Rs. 8.88 crores registered growth of

3%. The company is fully focused on this business which has significant value potential.

The formulations exports at Rs. 129.08 crores registered growth of 7% during the quarter. The exports of formulations to Rest of the world markets at Rs. 98.28 crores registered growth of 32% in Rupee terms.

The exports for the quarter are strictly not comparable due to the company's wholly owned subsidiary in Dubai commencing sales and distribution of the products in Russia-CIS countries during the Q1. This subsidiary will also undertake some of the expenses, and hence this arrangement is not expected to have significant impact on the company. The current political situation in Russia and Ukraine has impacted sales and the company is controlling expenses to minimize the impact on bottom line. The company is observing the situation very closely for its strategy for this market.

The API business with sales for the quarter at Rs. 28.49 crores registered growth of 5%. The product development and miscellaneous sales income during the quarter amounted to Rs. 2.62 crores.

The new capex spend is progressing well.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine, CIS countries and South Africa. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D and regulatory set-up for development of new drug delivery system and formulations, filing of DMFs and ANDAs. Its State-of-the-Art manufacturing facilities are approved by health authorities of regulated markets.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:

M.C. Mehta
Company Secretary- General Manager
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 24822311

-- x --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.